

Resource Summary Report

Generated by [SPARC SAWG](#) on Aug 14, 2026

B6.Cg-Thy1^a/Cy Tg(TcraTcrb)8Rest/J

RRID:IMSR_JAX:005023

Type: Organism

Proper Citation

RRID:IMSR_JAX:005023

Organism Information

URL: <https://www.jax.org/strain/005023>

Proper Citation: RRID:IMSR_JAX:005023

Description: Mus musculus with name B6.Cg-Thy1^a/Cy Tg(TcraTcrb)8Rest/J from IMSR.

Species: Mus musculus

Synonyms: B6.Cg Thy1-Tg(TcraTcrb)8Rest/J. pmel-1. C57BL/6-Tg(TcraTcrb)8Rest/J

Notes: gene symbol note: transgene insertion 8; Nicholas Restifo|thymus cell antigen 1; theta|T cell receptor alpha chain|T cell receptor beta chain; mutant strain|congenic strain: Tg(TcraTcrb)8Rest|Thy1|Tcra|Tcrb

Affected Gene: transgene insertion 8; Nicholas Restifo|thymus cell antigen 1; theta|T cell receptor alpha chain|T cell receptor beta chain

Genomic Alteration: transgene insertion 8; Nicholas Restifo|a variant

Catalog Number: JAX:005023

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.Cg-Thy1^a/Cy Tg(TcraTcrb)8Rest/J

Record Creation Time: 20250513T053647+0000

Record Last Update: 20260808T050849+0000

Ratings and Alerts

No rating or validation information has been found for B6.Cg-Thy1^a/Cy Tg(TcraTcrb)8Rest/J.

No alerts have been found for B6.Cg-Thy1^a/Cy Tg(TcraTcrb)8Rest/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 94 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Morgado-Cáceres P, et al. (2026) DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models. *Oncoimmunology*, 15(1), 2606497.

Salazar-Cavazos E, et al. (2026) Stochasticity in cancer immunotherapy stems from rare but functionally critical Spark T cells. *Cell*, 189(4), 1074.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. *Cell reports. Medicine*, 7(4), 102706.

Hammons JN, et al. (2026) Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma. *Hepatology (Baltimore, Md.)*, 84(1), 20.

Jiang H, et al. (2026) IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. *Immunity*, 59(1), 177.

Wittling MC, et al. (2026) T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy. *Cancer immunology research*, 14(3), 463.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. *Cancer research*, 86(11), 2688.

Seishima N, et al. (2025) Enhancing DC cancer vaccine by allogeneic MHC class II expression and Treg depletion. *JCI insight*, 10(16).

Pretto S, et al. (2025) A functional single-cell metabolic survey identifies Elov11 as a target to enhance CD8+ T cell fitness in solid tumours. *Nature metabolism*, 7(3), 508.

Zhang R, et al. (2025) USP30 inhibition augments mitophagy to prevent T cell exhaustion. *Science advances*, 11(33), eadv6902.

Ando Y, et al. (2025) Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system. *Oncoimmunology*, 14(1), 2437211.

Labiano S, et al. (2025) Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. *Cell reports. Medicine*, 6(7), 102204.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. *Cell*.

Frisch AT, et al. (2025) Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. *Cell metabolism*, 37(4), 870.

Srivastava J, et al. (2025) Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. *Cancer research*, 85(12), 2268.

Zuo Y, et al. (2025) IL-36 γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity. *Cancer cell*.

Cole AC, et al. (2025) Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. *Cancer cell*, 43(9), 1697.

Mortazavi Farsani SS, et al. (2025) Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy. *Cell metabolism*, 37(6), 1294.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOA as a potential immunotherapy. *Cell*, 188(18), 5062.

Vadovics M, et al. (2025) Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications. *Nature nanotechnology*, 20(9), 1312.